Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2004 1
2005 1
2006 3
2007 5
2008 9
2009 13
2010 14
2011 11
2012 17
2013 5
2014 7
2015 1
2016 4
2017 5
2018 3
2019 3
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 21117386

101 results
Results by year
Filters applied: . Clear all
Page 1
The incretin system in the management of type 2 diabetes mellitus.
Stephens JW. Stephens JW. Clin Med (Lond). 2010 Oct;10(5):491-5. doi: 10.7861/clinmedicine.10-5-491. Clin Med (Lond). 2010. PMID: 21117386 Free PMC article. Review. No abstract available.
Understanding the incretin effect.
Seino Y. Seino Y. J Clin Endocrinol Metab. 2011 Apr;96(4):934-5. doi: 10.1210/jc.2011-0329. J Clin Endocrinol Metab. 2011. PMID: 21474688 No abstract available.
Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B. Cariou B. Diabetes Metab. 2012 Oct;38(4):298-308. doi: 10.1016/j.diabet.2012.04.003. Epub 2012 Jun 4. Diabetes Metab. 2012. PMID: 22672960 Review.
Incretin based therapies: bone protective effects.
Chakhtoura M, Azar ST. Chakhtoura M, et al. Endocr Metab Immune Disord Drug Targets. 2013 Dec;13(4):289-94. doi: 10.2174/18715303113136660046. Endocr Metab Immune Disord Drug Targets. 2013. PMID: 24138054 Review.
[Antidiabetics and the incretin system].
Høibraaten E, Folkersen J. Høibraaten E, et al. Tidsskr Nor Laegeforen. 2008 Sep 11;128(17):1985. Tidsskr Nor Laegeforen. 2008. PMID: 18787580 Free article. Norwegian. No abstract available.
Incretins: what does the future hold?
Edelman SV. Edelman SV. Diabetes Technol Ther. 2005 Oct;7(5):809-12. doi: 10.1089/dia.2005.7.809. Diabetes Technol Ther. 2005. PMID: 16241889 Review. No abstract available.
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S. Russell S. Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Int J Clin Pharm. 2013. PMID: 23263796 Review.
New therapies for diabetes.
Green DE. Green DE. Clin Cornerstone. 2007;8(2):58-63; discussion 64-5. doi: 10.1016/s1098-3597(09)60008-9. Clin Cornerstone. 2007. PMID: 18357956 Review.
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M. Nauck M. Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5. Diabetes Obes Metab. 2016. PMID: 26489970 Free PMC article. Review.
[DPP-IV inhibitors and GLP-1 analogues].
Zettl H, Steinhilber D. Zettl H, et al. Pharm Unserer Zeit. 2010 Mar;39(2):108-13. doi: 10.1002/pauz.201000357. Pharm Unserer Zeit. 2010. PMID: 20196037 Review. German. No abstract available.
101 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback